SGMT logo

SAGIMET BIOSCIENCES INC-A

SGMTNASDAQ
🏆 #2836 by market capEarnings Nov 16 · PreUS Equity
$373.14▲ $10.11 (+2.71%)
Simulated price
🔔
Track SGMT
Get earnings, price moves & breaking news on Telegram
Track
24h▲ 2.7%
7d▲ 3270.7%
14d▲ 3467.3%
30d▲ 3436.9%
ytd▲ 6203.0%
1y▲ 5280.5%
🏦Market Cap
$612M
Small Cap
📈Revenue Growth (YoY)
—
📊Gross Margin
—
💵FCF Margin
—
⚖️P/S Ratio
—
Otter Score
76
Good

Trading Snapshot

Day Range
$370.23 – $378.14
52-Week Range
$4.50 – $11.45
Volume
$2.87B
Avg Volume
$3.01B
Shares Outstanding
61.8M
Next Earnings
Dec 9, 2026

Fundamentals Snapshot

Annual Revenue
$153M
Last Q Revenue
$36M
P/E Ratio
—
P/S Ratio
—
EPS (TTM)
$-1.28
Dividend Yield
—
Dilution (1yr)
+1.0%

Why Investors Own SGMT

  • ✓High-growth profile — revenue up +9.0% YoY with expanding US Equity exposure.
  • ✓Healthy economics — 33% gross margin and 6% free-cash-flow margin.
  • ✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks

Execution delays, intensifying competition, and valuation compression if growth decelerates.

SGMT logo

SAGIMET BIOSCIENCES INC-A

SGMT
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$57M▲ +4.5% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$46M▲ +7.6% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
32.5M▲ +1.0% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$35M▼ −$41M YoY
StockOtter · stockotter.space

About SAGIMET BIOSCIENCES INC-A

Sagimet Biosciences Inc., a clinical-stage biopharmaceutical company, develops novel therapeutics called fatty acid synthase (FASN) inhibitors for the treatment of diseases that result from dysfunctional metabolic and fibrotic pathways in the United States. The company’s lead drug candidate is Denifanstat, an oral, once-daily pill and selective FASN inhibitor for the treatment of metabolic dysfunction-associated steatohepatitis, acne, and select forms of cancer. It also develops TVB-3567, a FASN inhibitor for the treatment of acne indication; and other oncology programs, such as solid tumor and glioblastoma. The company was formerly known as 3-V Biosciences, Inc. and changed its name to Sagimet Biosciences Inc. in August 2019. Sagimet Biosciences Inc. was incorporated in 2006 and is headquartered in San Mateo, California.

🦦

Otter Score Breakdown

How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
💎Quality★★★★★
🚀Growth★★★★★
⚖️Valuation★★★★★
⚡Momentum★★★★★
💧Dilution★★★★★
Overall Score
Good
76/100

Analyst Price Target

ⓘ
Average Target
$405.92
▲ +8.8% Upside
High Target$491.06
Low Target$374.68
Based on 39 analysts

Latest News & Updates

🚀
Bloomberg·2h ago

SAGIMET BIOSCIENCES INC-A tops quarterly estimates as demand accelerates

Revenue grew double digits with management guiding above consensus; margins continued to expand.

🛰️
MarketWatch·5h ago

Analysts lift SGMT price targets on improving margins

Several firms raised targets, citing stronger free cash flow and a healthier backlog.

🌌
Reuters·1d ago

SAGIMET BIOSCIENCES INC-A announces new agreement to expand its footprint

The move broadens the company’s reach and could add incremental revenue over the next year.